Abbott Laboratories (ABT) Stock Analysis 2026

HealthcareMedical Devices
$104.57
as of 2026-10-29
-22.4% (52-week)50D MA $105.30  |  200D MA $105.84

BriMind AI Score

Proprietary
51
Neutral
Price CAGR
11.6%
1Y Return
-18.2%
Analyst Upside
+16.0%
Rev Growth
13.0%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

ABT Revenue & Profitability Breakdown

This chart shows how ABT's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$46.58B
Cost of Revenue
-$20.10B
Gross Profit
$26.48B56.8% margin
Operating Expenses
-$19.63B
Operating Income
$6.85B14.7% margin
Tax & Other
-$1.43B
Net Income
$5.42B11.6% margin
Gross Margin
56.8%
Operating Margin
14.7%
Net Margin
11.6%
EBITDA Margin
26.0%

Key Financial Metrics

Abbott Laboratories trades at a trailing P/E of 32.99x, generates $7.21B in free cash flow, runs a debt/equity ratio of 63.21, and converts shareholder equity into profit at a 10.6% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$176.41B
Enterprise Value
$239.11B
P/E (Trailing)
32.99
P/E (Forward)
16.81
PEG Ratio
1.87
EV / EBITDA
21.70
Price / Sales
5.49
Price / Book
3.45
Revenue
$46.58B
Revenue Growth
13.0%
Earnings Growth
-47.5%
EBITDA
$11.02B
EPS (Trailing)
$3.09
EPS (Forward)
$6.07
Gross Margin
56.8%
Operating Margin
14.7%
Net Margin
11.6%
Return on Equity
10.6%
Return on Assets
5.3%
Free Cash Flow
$7.21B
Total Cash
$6.84B
Total Debt
$13.29B
Debt / Equity
63.21
Current Ratio
1.38
Quick Ratio
0.80
Beta
0.59
Dividend Yield
2.5%
Payout Ratio
79.0%
Insider Ownership
0.5%
Inst. Ownership
81.8%
Short % Float
1.4%
Book Value / Share
$29.54

Wall Street Analyst Consensus

25 analysts covering Abbott Laboratories currently lean toward a Buy rating, with a mean 12-month price target of $120.26 (+15.0% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingBuy(25 analysts)
SellStrong Buy
Low Target$120.1214.9%
Mean Target$120.26+15.0% upside
High Target$159.00+52.1%

Intrinsic Value Estimates for ABT

We use 4 valuation models to estimate ABT's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Technical Price Signals

ABT is currently in a death cross pattern, trading below its 50-day average of $105.30 and below its 200-day average of $105.84. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$104.57
50-Day MA
$105.30
▼ Price below
200-Day MA
$105.84
▼ Price below
Death Cross Pattern
Price below both MAs — bearish signal
Read the full ABT in-depth report
Seven-method valuation, AI Score, blended price target, and a 5-year Monte Carlo simulation for ABT.

Compare ABT with Peers

ABT vs MDTAbbott Laboratories vs Medtronic — Diversified MedTech
ABT vs BAXAbbott Laboratories vs Baxter International — Which Hea
BDX vs ABTBecton Dickinson vs Abbott — Which Medical Products Gia
ISRG vs ABTIntuitive Surgical vs Abbott — Which Medtech Stock Wins
ABT vs ZBHAbbott vs Zimmer Biomet — Diversified MedTech vs Orthop
ABT vs DXCMAbbott vs DexCom — Freestyle Libre vs G7: The CGM Showd
ABT vs SYKAbbott Laboratories vs Stryker — Diversified Medtech &
BSX vs ABTBoston Scientific vs Abbott Laboratories — Which Med-Te

Further Reading

Research and guides that put ABT’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

SectorsBest Healthcare Stocks to Buy in 2026FundamentalsHow to Read a 10-K Annual Report: Complete Investor GuideFundamentals10 Stock Analysis Tools Every Investor Should Know AboutFundamentalsFactor Investing Guide 2026: Value, Momentum, Quality & Low Volatility — Which Factors Work?

More Healthcare Stock Analysis

In-depth reports on companies operating alongside ABT — business models, bull and bear cases, and the metrics that matter.

GEHCGE HealthCare Technologies Inc.Medical DevicesZBHZimmer Biomet Holdings, Inc.Medical DevicesSYKStryker CorporationMedical DevicesSTESTERIS plcMedical DevicesDXCMDexCom, Inc.Medical DevicesEWEdwards Lifesciences CorporationMedical DevicesBSXBoston Scientific CorporationMedical DevicesMDTMedtronic plcMedical Devices

Unlock the Full ABT Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis